ATAI Life SciencesATAI
Market Cap: $200M
About: ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.
Employees: 83
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
11% more call options, than puts
Call options by funds: $200K | Put options by funds: $180K
0% more funds holding
Funds holding: 87 [Q1] → 87 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
0% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 15
1.92% less ownership
Funds ownership: 9.05% [Q1] → 7.13% (-1.92%) [Q2]
13% less repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 16
46% less capital invested
Capital invested by funds: $29.6M [Q1] → $15.9M (-$13.7M) [Q2]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 1,161%upside $15 | Buy Reiterated | 30 Aug 2024 |
HC Wainwright & Co. Patrick Trucchio 30% 1-year accuracy 40 / 135 met price target | 1,161%upside $15 | Buy Reiterated | 31 Jul 2024 |
Financial journalist opinion
Based on 7 articles about ATAI published over the past 30 days